Skip to content
Review Open access

Redifferentiation therapy prior to radioiodine in refractory differentiated thyroid cancer: A systematic review and meta-analysis

Sep 2026 · Revista Colombiana de Endocrinología, Diabetes & Metabolismo · 0 citations · 30 references

Abstract

Background: Radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) has a poor prognosis. Constitutive MAPK activation, frequently driven by BRAF V600E or RAS alterations, suppresses thyroid-specific genes and sodium-iodide symporter expression. Short-course BRAF and/or MEK inhibition before RAI aims to restore iodine avidity. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA 2020. PubMed, Embase, CENTRAL, ClinicalTrials.gov, and Google Scholar were searched from inception through March 31, 2025, for prospective studies of short-course BRAF and/or MEK inhibition undertaken with the protocolized intention of restoring RAI uptake before therapeutic RAI (PROSPERO: CRD1371813). Random-effects models with REML estimation and logit transformation were used for proportions. Risk of bias was assessed with ROBINS-I and certainty with GRADE. Results: Five non-randomized single-arm studies (N=72) met the revised eligibility criteria; four studies (n=48) contributed to the primary meta-analysis. The pooled proportion with restored detectable RAI uptake was 62.3% (95% CI 47.8%-74.8%; I²=0%). When the therapeutic dosimetric threshold reported by Ho et al. was used, the pooled estimate was 57.8% (95% CI 44.0%-71.5%). Excluding Ho et al., it yielded 63.5% (95% CI 45.7%-81.4%). No included study published a hazard ratio for progression-free survival; progression-free and overall survival were therefore synthesized narratively. Adverse-event rates were not pooled because attribution, grading, and exposure duration differed across studies. No treatment-related deaths were reported. Certainty of the evidence was very low for all outcomes. Conclusions: Short-course MAPK inhibitor-based redifferentiation can restore RAI uptake in selected patients with RAI-refractory DTC, but uptake is a surrogate outcome and does not establish survival benefit. The evidence is insufficient to determine whether efficacy differs by mutation subtype. Controlled, biomarker-stratified trials using standardized imaging and clinically relevant outcomes are needed.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.